2 November 2018

First patient treated with ILB in TIKOMED’s clinical trial for ALS

Viken, November 2nd, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological diseases, announce today that the first patient with Amyotrophic Lateral Sclerosis (ALS) has been treated with the company’s investigational drug ILB, in the on-going clinical trial at Sahlgrenska University Hospital in Gothenburg, Sweden.

Anders Svenson M.D., Chief Medical Officer of TIKOMED, commented, “We are very pleased that our clinical trial, with our investigational drug ILB for the treatment of ALS, is well underway and that the trial’s first patient has successfully completed the four-week treatment period with ILB. We believe this clinical trial, conducted at Sahlgrenska University Hospital, will demonstrate the safety and tolerability of ILB in the treatment of ALS”.

With Dr. Lennart Persson as principal investigator, the clinical trial is conducted at and in collaboration with Sahlgrenska University Hospital in Gothenburg. 15 patients with ALS will receive ILB for a four-week treatment period followed by a three-month, follow-up period.

Anders Kristensson, Chief Executive Officer of TIKOMED, commented, “With ILB we present a potentially new class of drug which can address the underlying causes of neurodegeneration, as seen in a chronic disease such as ALS. We are committed to bringing ILB through our ALS clinical trial program and hopefully one step closer to ALS sufferers battling this fatal disease”.

Tikomed will also be running a phase II ALS study in collaboration with Birmingham University in Birmingham, UK. In this trial, 15 patients with ALS will receive ILB for a ten-week treatment period.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

30 November 2018
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
VIKEN, Sweden, November 19, 2018 (Newswire) -TIKOMED, a specialty pharmaceutical company developing IBsolvMIR, an infusion…
Read More
20 August 2018
TIKOMED to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission
Viken, August 20th, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for…
Read More
14 August 2018
TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital
VIKEN, Sweden, August 14, 2018 – ​TIKOMED, a specialty pharmaceutical company focused on developing therapeutics…
Read More
SEE MORE